JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 48:43-50, doi:10.1016/j.jacc.2006.03.035 (Published online 7 June 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kodama, Y.
Right arrow Articles by Kugiyama, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kodama, Y.
Right arrow Articles by Kugiyama, K.

Atorvastatin Increases Plasma Soluble Fms-Like Tyrosine Kinase-1 and Decreases Vascular Endothelial Growth Factor and Placental Growth Factor in Association With Improvement of Ventricular Function in Acute Myocardial Infarction

Yasushi Kodama, MD, Yoshinobu Kitta, MD, Takamitsu Nakamura, MD, Hajime Takano, MD, PhD, Ken Umetani, MD, PhD, Daisuke Fujioka, MD, Yukio Saito, MD, Ken-ichi Kawabata, MD, Jyun-ei Obata, MD, PhD, Akira Mende, MD, Tsuyoshi Kobayashi, MD and Kiyotaka Kugiyama, MD, PhD*

Department of Internal Medicine II, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan.


Figure 1
View larger version (39K):

[in a new window]
  		Figure 1 Comparison of soluble Fms-like tyrosine kinase-1 (sFlt-1) (A), free vascular endothelial growth factor (VEGF) (B), free placental growth factor (PlGF) (C), and total VEGF (D) levels during the follow-up period after AMI in patients treated with atorvastatin (n = 25) and placebo (n = 25). *p < 0.05 vs. respective levels in the acute phase of myocardial infarction. {dagger}p < 0.05 vs. healthy control subjects.

 

Figure 2
View larger version (15K):

[in a new window]
  		Figure 2 Comparisons of the percentage changes in the plasma levels at 2 weeks and 6 months after acute myocardial infarction relative to the levels at acute phase of myocardial infarction (=100%) between the two treatment groups. (A) sFlt-1; (B) free VEGF; (C) free PlGF. {dagger}p < 0.05 vs. respective levels at 2 weeks after MI. Abbreviations as in Figure 1.

 

Figure 3
View larger version (26K):

[in a new window]
  		Figure 3 Comparison of changes in left ventricular ejection fraction (LVEF) from 2 weeks to 6 months after acute myocardial infarction in patients treated with atorvastatin (n = 25) and placebo (n = 25).

 

Figure 4
View larger version (24K):

[in a new window]
  		Figure 4 Correlations between percent changes in LVEF and in plasma levels of sFlt-1, free VEGF, or free PlGF from 2 weeks to 6 months after acute myocardial infarction in patients treated with atorvastatin (n = 25; solid circles) and placebo (n = 25; open circles). Abbreviations as in Figures 1 and 3.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.